Last reviewed · How we verify
Multiple low dose cyclophosphamide
At a glance
| Generic name | Multiple low dose cyclophosphamide |
|---|---|
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma (PHASE1)
- BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (PHASE1)
- Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia (PHASE2)
- Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) (PHASE2)
- Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PHASE2)
- A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. (PHASE1)
- Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multiple low dose cyclophosphamide CI brief — competitive landscape report
- Multiple low dose cyclophosphamide updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI